The deregistration is a routine post-merger formality. BLFS common stock has been acquired and delisted; monitor Repligen (RGEN) for any integration updates or contingent value rights.
Price Chart
Executive Summary
BioLife Solutions, Inc. filed a Form 15-12G to terminate its SEC registration under Section 12(g) and suspend its duty to file reports, effective October 16, 2026. This follows the completion of its acquisition by Repligen Corporation on October 6, 2026, where BioLife merged into a Repligen subsidiary and became BioLife Solutions, LLC. The deregistration is a routine procedural step after a completed merger, as the company now has only one holder of record (Repligen).
Key Facts
- Form 15-12G filed to terminate registration under Section 12(g) and suspend reporting obligations under Sections 13 and 15(d) of the Exchange Act.
- Deregistration follows the completed merger of BioLife Solutions, Inc. into Repligen Corporation on October 6, 2026.
- Approximate number of holders of record as of the certification date: 1.
- BioLife Solutions, LLC is the successor by merger to BioLife Solutions, Inc., now a direct wholly owned subsidiary of Repligen Corporation.
Financial Impact
No financial impact — deregistration is a procedural step following the completed acquisition by Repligen Corporation.
Risk Factors
- No residual public market for BLFS shares — all holders were cashed out or converted in the merger.
- No further SEC filings from BioLife as a standalone public entity.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 15-12G Filing (Primary) | 0001193125-26-424049 |
| Document: 0001193125-26-424049-index-headers.html | 0001193125-26-424049 |
| Document: 0001193125-26-424049-index.html | 0001193125-26-424049 |
| Document: 0001193125-26-424049.txt | 0001193125-26-424049 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 9d ago | 15-12G | — | awaiting T+20 | — | — |
Oct 13, 2026 13d ago | EFFECT | — | awaiting T+20 | — | — |
Oct 13, 2026 13d ago | EFFECT | — | awaiting T+20 | — | — |
Oct 6, 2026 20d ago | 8-K | $39.00 | awaiting T+20 | — | — |
Sep 30, 2026 26d ago | 425 | $38.85 | awaiting T+20 | — | — |
Sep 30, 2026 26d ago | DEFA14A | $38.85 | awaiting T+20 | — | — |
Sep 24, 2026 4w ago | SC 13G | $38.58 | awaiting T+20 | — | — |
Sep 4, 2026 7w ago | DEFM14A | $35.38 $38.61 | ▲ +9.13% | ▲ +7.42% | — |
Jun 3, 2026 20w ago | 8-K | $27.25 $28.11 | ▲ +3.16% | ▲ +4.16% | — |
Apr 28, 2026 25w ago | 10-K/A | $19.99 $25.25 | ▲ +26.31% | ▲ +20.26% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers